04244nam 22003733 450 991088029260332120240609090313.01-4988-4520-7(MiAaPQ)EBC31460022(Au-PeEL)EBL31460022(CKB)32245698000041(EXLCZ)993224569800004120240609d2024 uy 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierClostridioides Difficile Colitis2024th ed.Los Angeles :Gideon Informatics, Incorporated,2024.©2024.1 online resource (108 pages)Intro -- Copyright -- Introduction: The GIDEON e-book series -- Table of Contents -- Clostridioides difficile colitis -- Epidemiology -- Agent -- Reservoir -- Vector -- Vehicle -- Incubation Period -- Diagnostic Tests -- Typical Adult Therapy -- Typical Pediatric Therapy -- Vaccine -- Clinical Hints -- Synonyms -- References -- Clinical -- References -- Distribution Map -- Images -- Global status -- References -- Algeria -- References -- Argentina -- References -- Australia -- References -- Austria -- References -- Bahrain -- References -- Bangladesh -- References -- Belarus -- References -- Belgium -- References -- Bermuda -- References -- Bosnia and Herzegovina -- References -- Brazil -- References -- Cameroon -- References -- Canada -- References -- The Canary Islands -- References -- Cape Verde -- References -- Chile -- References -- China -- References -- Colombia -- References -- Costa Rica -- References -- Croatia -- References -- The Czech Republic -- References -- The Democratic Republic of Congo -- References -- Denmark -- References -- Egypt -- References -- Estonia -- Ethiopia -- References -- Finland -- References -- France -- References -- Georgia -- References -- Germany -- References -- Ghana -- References -- Greece -- References -- Guam -- Guatemala -- References -- Hong Kong -- References -- Hungary -- References -- Iceland -- References -- India -- References -- Indonesia -- References -- Iran -- References -- Iraq -- References -- Ireland -- References -- Israel -- References -- Italy -- References -- Ivory Coast -- References -- Jamaica -- References -- Japan -- References -- Jordan -- References -- Kenya -- References -- Kuwait -- References -- Laos -- References -- Latvia -- Lebanon -- References -- Lithuania -- Luxembourg -- Malawi -- References -- Malaysia -- References -- Malta -- Mexico -- References -- Montenegro.References -- Mozambique -- References -- The Netherlands -- References -- New Caledonia -- References -- New Zealand -- References -- Nigeria -- References -- North Macedonia -- Northern Ireland -- References -- Norway -- References -- Pakistan -- References -- Peru -- References -- The Philippines -- References -- Poland -- References -- Portugal -- References -- Qatar -- References -- South Korea -- References -- Romania -- References -- The Russian Federation -- References -- Saudi Arabia -- References -- Scotland -- References -- Serbia -- References -- Singapore -- References -- Slovakia -- References -- Slovenia -- References -- South Africa -- References -- Spain -- References -- Sweden -- References -- Switzerland -- References -- Taiwan -- References -- Tanzania -- References -- Thailand -- References -- Timor-Leste -- References -- Trinidad and Tobago -- References -- Turkey -- References -- The United Kingdom -- References -- The United States -- References -- Vietnam -- References -- Zambia -- References -- Zimbabwe -- References -- Vaccines &amp -- Immunoglobulins -- Bezlotoxumab -- Mechanism of Action -- Typical Adult Dosage -- Typical Pediatric Dosage -- Subsequent booster -- Toxic Effects for Bezlotoxumab (3 listed) -- Contraindications for Bezlotoxumab (0 listed) -- Trade names of Bezlotoxumab (1 listed) -- About GIDEON.Berger Stephen1210032GIDEON science team Gideon science1765422MiAaPQMiAaPQMiAaPQBOOK9910880292603321Clostridioides Difficile Colitis4207311UNINA